UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The sphingosine‐1‐phosphate receptor 1 modulator ponesimod repairs cuprizone‐induced demyelination and induces oligodendrocyte differentiation

The FASEB journal, 2024-01, Vol.38 (2), p.e23413-n/a

2024

Volltextzugriff (PDF)

Disease activity after short-term interruption of ponesimod versus teriflunomide in relapsing multiple sclerosis patients

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A68-A68

2023

Volltextzugriff (PDF)

Longitudinal clinical and MRI-outcomes in relapsing multiple sclerosis patients after short-term ponesimod treatment-interruption and re-initiation

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A69-A69

2023

Volltextzugriff (PDF)

Preservation of myelin in patients with relapsing multiple sclerosis treated with ponesimod compared to teriflunomide

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A72-A72

2023

Volltextzugriff (PDF)

The cystathionine‐β‐synthase domains on the guanosine 5′’‐monophosphate reductase and inosine 5′‐monophosphate dehydrogenase enzymes from Leishmania regulate enzymatic activity in response to guanylate and adenylate nucleotide levels

Molecular microbiology, 2016-06, Vol.100 (5), p.824-840

2016

Volltextzugriff (PDF)

Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies

BMC neurology, 2024-10, Vol.24 (1), p.378-12, Article 378

2024

Volltextzugriff (PDF)

Analysis and Evaluation of Ponesimod Hepatic Safety Data (P1-1.Virtual)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

Ponesimod Shows Improved Effect on Brain Volume Compared with Other DMTs, A Model Based Meta-Analysis (P1-1.Virtual)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

Uncontrolled Myasthenia Gravis Can Contribute to Additional Stress Burden and Adverse Mental Health Experiences (P4-11.019)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Effect of Ponesimod Compared With Teriflunomide on Treatment With Concomitant Corticosteroids for Relapse in Patients with Relapsing Forms of Multiple Sclerosis (P5-4.008)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

Relationships Between Brain Volume and Disability, Cognition, Motor Function, and MS-Fatigue in Relapsing Multiple Sclerosis: MS-Fatigue and Ambulation Move at Their Own Pace (P1-1.Virtual)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

Longitudinal Clinical and MRI Outcomes in Relapsing Multiple Sclerosis (RMS) Patients After Short-term Ponesimod Treatment Interruption and Re-initiation (P6-3.007)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Patients treated with ponesimod demonstrate reductions in serum neurofilament light chain levels

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A72-A72

2023

Volltextzugriff (PDF)

Étude d’extension de phase III du Ponesimod dans la sclérose en plaques récurrente : résultats d’efficacité

Revue neurologique, 2024-04, Vol.180, p.S157-S158

2024

Volltextzugriff (PDF)

A systematic literature review of the measurement of patient-reported fatigue in studies of disease modifying therapies for multiple sclerosis

Multiple sclerosis and related disorders, 2024-11, Vol.91, p.105846, Article 105846

2024

Volltextzugriff (PDF)

Mise à jour des données de sécurité dans la phase III d’extension du Ponesimod dans la SEP-R

Revue neurologique, 2024-04, Vol.180, p.S158-S158

2024

Volltextzugriff (PDF)

Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis

OncoTargets and therapy, 2015-01, Vol.8 (default), p.911-919

2015

Volltextzugriff (PDF)

The cystathionine-[beta]-synthase domains on the guanosine 5''-monophosphate reductase and inosine 5'-monophosphate dehydrogenase enzymes from Leishmania regulate enzymatic activity in response to guanylate and adenylate nucleotide levels

Molecular microbiology, 2016-06, Vol.100 (5), p.824

2016

Volltextzugriff (PDF)

Severity and worsening of fatigue among individuals with multiple sclerosis

Multiple sclerosis journal - experimental, translational and clinical, 2023-04, Vol.9 (2), p.20552173231167079-20552173231167079

2023

Volltextzugriff (PDF)

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda

Breast cancer research and treatment, 2012-05, Vol.133 (1), p.217-226

2012

Volltextzugriff (PDF)

ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity

Investigational new drugs, 2013-12, Vol.31 (6), p.1409-1423

2013

Volltextzugriff (PDF)

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda^sup ?

Breast cancer research and treatment, 2012-05, Vol.133 (1), p.217

2012

Volltextzugriff (PDF)

Abstract C161: Modulation of thymidine phosphorylase (TP) expression in breast cancer cell lines exposed to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C161-C161

2009

Volltextzugriff (PDF)

Abstract A44: Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda

Clinical cancer research, 2010-07, Vol.16 (14_Supplement), p.A44-A44

2010

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Women's Health

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(24)

Sprache

Englisch
(22)
Französisch
(2)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The sphingosine‐1‐phosphate receptor 1 modulator ponesimod repairs cuprizone‐induced demyelination and induces oligodendrocyte differentiation

Disease activity after short-term interruption of ponesimod versus teriflunomide in relapsing multiple sclerosis patients

Longitudinal clinical and MRI-outcomes in relapsing multiple sclerosis patients after short-term ponesimod treatment-interruption and re-initiation

Preservation of myelin in patients with relapsing multiple sclerosis treated with ponesimod compared to teriflunomide

The cystathionine‐β‐synthase domains on the guanosine 5′’‐monophosphate reductase and inosine 5′‐monophosphate dehydrogenase enzymes from Leishmania regulate enzymatic activity in response to guanylate and adenylate nucleotide levels

Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies

Analysis and Evaluation of Ponesimod Hepatic Safety Data (P1-1.Virtual)

Ponesimod Shows Improved Effect on Brain Volume Compared with Other DMTs, A Model Based Meta-Analysis (P1-1.Virtual)

Uncontrolled Myasthenia Gravis Can Contribute to Additional Stress Burden and Adverse Mental Health Experiences (P4-11.019)

Effect of Ponesimod Compared With Teriflunomide on Treatment With Concomitant Corticosteroids for Relapse in Patients with Relapsing Forms of Multiple Sclerosis (P5-4.008)

Relationships Between Brain Volume and Disability, Cognition, Motor Function, and MS-Fatigue in Relapsing Multiple Sclerosis: MS-Fatigue and Ambulation Move at Their Own Pace (P1-1.Virtual)

Longitudinal Clinical and MRI Outcomes in Relapsing Multiple Sclerosis (RMS) Patients After Short-term Ponesimod Treatment Interruption and Re-initiation (P6-3.007)

Patients treated with ponesimod demonstrate reductions in serum neurofilament light chain levels

Étude d’extension de phase III du Ponesimod dans la sclérose en plaques récurrente : résultats d’efficacité

A systematic literature review of the measurement of patient-reported fatigue in studies of disease modifying therapies for multiple sclerosis

Mise à jour des données de sécurité dans la phase III d’extension du Ponesimod dans la SEP-R

Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis

The cystathionine-[beta]-synthase domains on the guanosine 5''-monophosphate reductase and inosine 5'-monophosphate dehydrogenase enzymes from Leishmania regulate enzymatic activity in response to guanylate and adenylate nucleotide levels

Severity and worsening of fatigue among individuals with multiple sclerosis

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda

ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda^sup ?

Abstract C161: Modulation of thymidine phosphorylase (TP) expression in breast cancer cell lines exposed to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839

Abstract A44: Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda

Aktive Filter

Suchergebnisse filtern